Active — Not RecruitingNot Applicable

Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application

China200 participantsStarted 2024-06-03

Plain-language summary

At least 50 patients with intracranial infection receiving anti-infective drugs such as vancomycin, meropenem, linezolid, cefoperazone sulbactam, ceftazidime and avibactam were included in each group for pharmacokinetic study, and the outcomes and adverse events of intracranial infection treatment were observed.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years old;
✓. clinically diagnosed as central infection (cerebrospinal fluid culture is positive with clinical infection symptoms) or suspected as central infection (abnormal cerebrospinal fluid examination, such as hypoglycemia, \&lt; 50%; High protein, \&gt; 50 mg/dl; The number of cells increased with clinical infection symptoms, but no cerebrospinal fluid culture was positive)
✓. receiving anti-infection treatment such as vancomycin or meropenem or linezolid or cefoperazone sulbactam;
✓. Sign the informed consent form.

Exclusion criteria

✕. There is no cerebrospinal fluid to determine the concentration;
✕. allergic to drugs;
✕. Other factors that researchers think are not suitable for inclusion.

What they're measuring

Cerebrospinal fluid concentration of anti-infective drugs

Timeframe: 2023-2026

Trial details

NCT IDNCT06729619

SponsorXueyan Cui

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12-31

View on ClinicalTrials.gov More Intracranial Infection trials